Along with its dismal half-year financial reports, UK-based AstraZeneca announced it was halting six pipeline programs.
Eli Lilly reported better-than-expected second-quarter 2016 sales and predicted average annual revenue growth of at least 5 percent through the end of the decade.
Allergan Plc reported a higher-than-expected quarterly profit and said it would buy back up to $10 billion in company stock.
Biopharma company Chimerix reported top-line results from an interim analysis of the AdVise trial of brincidofovir for serious adenovirus (AdV) infection.
Regeneron Pharmaceuticals, facing slowing sales of blockbuster eye drug Eylea, said it was making substantial progress in securing more insurance coverage for cholesterol drug Praluent.
Pfizer Inc. reported quarterly results that blew past analyst estimates on sales of its new cancer and arthritis treatments and the acquisition last year of the hospital products company Hospira.
Strong demand for Shire’s top-selling Vyvanse drug helped to lift the company’s first-quarter earnings by better-than-expected 12 percent.
Improving margins and growing demand for new drugs lifted GlaxoSmithKline’s underlying earnings a better-than-expected 14 percent in the first quarter.
Biogen Inc. reported a better-than-expected quarterly profit as the company cut costs and demand rose for Tecfidera, its key drug for multiple sclerosis.
January 28, 2016By Alex Keown, BioSpace.com Breaking News Staff BOSTON – An issue of patient compliance in taking Vertex (VRTX)’s new blockbuster cystic fibrosis drug Orkambi is at the root of why the company has not issued sales guidance yet, the Boston Business Journal reported this morning. During the J.P. Morgan Healthcare Conference earlier […]